{"id":"fexuprazan-hydrochloride","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Unlike proton pump inhibitors (PPIs) that irreversibly bind to the H+/K+-ATPase, fexuprazan competitively blocks potassium binding to the pump, allowing for faster onset and offset of acid suppression. This mechanism provides rapid and sustained gastric pH elevation, making it effective for acid-related disorders. The reversible binding may offer advantages in terms of drug interactions and recovery of acid secretion.","oneSentence":"Fexuprazan hydrochloride is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the H+/K+-ATPase pump in gastric parietal cells to reduce gastric acid secretion.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:46:27.733Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"}]},"trialDetails":[{"nctId":"NCT05946135","phase":"PHASE4","title":"Efficacy of Fexuprazan for Prevention or Control of Gastritis Symptoms in Patients on Treatment With Systemic Steroids","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2023-11-07","conditions":"Patients on Treatment With Systemic Steroids","enrollment":42},{"nctId":"NCT05660122","phase":"","title":"A Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-11-11","conditions":"Gastroesophageal Reflux Disease","enrollment":2852},{"nctId":"NCT06948487","phase":"","title":"Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis","status":"RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2025-06-17","conditions":"Gastritis","enrollment":12000},{"nctId":"NCT05886933","phase":"","title":"Study to Evaluate the Efficacy and Safety of FEXUCLUE Tablet","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2023-05-22","conditions":"Gastroesophageal Reflux Disease","enrollment":9846}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fexuclue Tablet"],"phase":"marketed","status":"active","brandName":"Fexuprazan Hydrochloride","genericName":"Fexuprazan Hydrochloride","companyName":"Daewoong Pharmaceutical Co. LTD.","companyId":"daewoong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fexuprazan hydrochloride is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the H+/K+-ATPase pump in gastric parietal cells to reduce gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}